Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

GI Dynamics

Explore full profile

Medical device company developing therapies for the treatment of type 2 diabetes and related metabolic diseases

Boston, United StatesFounded 2003Biotech & Life Sciences
Valuation $90M Market cap · 2009
Revenue $1.3M Latest reported FY

About GI Dynamics

GI Dynamics, Inc. is a medical device company focused on addressing the global diabetes and obesity epidemic. The company operates primarily in the healthcare market, targeting patients with type 2 diabetes and obesity. Their flagship product, EndoBarrier, is a minimally invasive device designed to help manage these conditions by mimicking the effects of gastric bypass surgery without the need for invasive procedures.

EndoBarrier is currently in the investigational stage and is not yet approved for sale in the European Union or the United States. It is limited by Federal US Law to investigational use only. The device works by creating a physical barrier between food and the wall of the intestine, which can lead to improved blood sugar levels and weight loss.

GI Dynamics serves a niche market of patients who are struggling with type 2 diabetes and obesity and are looking for non-surgical treatment options. The company also collaborates with healthcare providers and researchers to conduct clinical trials and gather data on the efficacy and safety of EndoBarrier.

The business model of GI Dynamics revolves around the development, clinical testing, and eventual commercialization of EndoBarrier. They generate revenue through funding from investors and partnerships with healthcare institutions. Once EndoBarrier receives regulatory approval, the company plans to make money by selling the device to healthcare providers and directly to patients.

In summary, GI Dynamics is a healthcare-focused company that aims to provide innovative solutions for managing type 2 diabetes and obesity through its investigational product, EndoBarrier. The company is currently in the clinical trial phase and relies on investor funding and partnerships for its operations.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2003
Headquarters
Boston, United States
Listing
IPO 2011
Employees
57
Open positions
None listed
Dealroom signal
50.1/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotech & Life Sciences, Personal Health, Diabetes, Biotechnology, Metabolism, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
PRIVATE PLACEMENT VCOther financing Sep 2020 $10M — Crystal Amber Fund —
POST IPO EQUITYOther financing Aug 2019 $10M — Crystal Amber Fund —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026 $1.3M 0%
2025 $1.3M 0%
2024 $1.3M 0%
2023 $1.3M 0%
2022 $1.3M 0%
2021 $1.3M 0%
2020 $1.3M —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

GI Dynamics website traffic

Latest recorded traffic for GI Dynamics is 1.5K monthly website visits, up 1150% over the last three months. GI Dynamics's team grew 1.8% over the past year.

Latest monthly visits1.5K 3-month web change+1150% 1-year team growth+1.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Advanced Technology Ventures
  • Polaris Partners
  • Domain Associates
  • Cutlass Capital
  • Angel Healthcare Investors
  • Medtronic

Series B and later1 investor entered at this stage

  • Crystal Amber Fund

Other known investors1 additional known investor

  • Lightstone Ventures
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇺🇸 United States66.7%
🇬🇧 United Kingdom18.5%
🇰🇷 South Korea3.7%
🇩🇪 Germany3.7%
🇮🇹 Italy3.7%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about GI Dynamics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See GI Dynamics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.